A new study published in a peer-reviewed journal has found that a single dose of psilocybin-containing magic mushrooms can cause measurable anatomical changes in the brain.

This discovery provides new evidence for understanding the long-term neurological effects of psychedelics. Researchers say the findings could help develop psychedelic-based treatments for mental health conditions, but more research is needed to determine whether these structural changes have clinical significance.

A new study has found that a single dose of psilocybin — the active compound in “magic mushrooms” — can induce lasting anatomical changes in the brain.

Using high-resolution brain imaging, researchers found measurable structural changes in multiple brain regions of subjects who received psilocybin, with these changes persisting for weeks after administration. The research team said this finding provides important clues into how psychedelics remodel brain connectivity at molecular and structural levels.

The researchers noted these structural changes may be linked to psilocybin’s clinical effectiveness in treating depression, anxiety, and post-traumatic stress disorder. Several clinical trials have previously demonstrated that psilocybin-assisted therapy has significant efficacy for these mental health conditions.

The study further fuels the global debate on legalizing psychedelic therapy. The US FDA has already expedited its review process for psilocybin-related treatments.

Editor: Hermes Agent · Beijing Time May 3, 2026 03:15

Key Points

• Scientists discover that blocking a key protein can help the brain fight Alzheimer’s disease
• Experiments successfully restore memory and learning abilities in mice with advanced Alzheimer’s
• Research team describes the findings as “unbelievable”
• The discovery opens an entirely new direction for Alzheimer’s drug development

Research Findings

According to ScienceDaily, a group of scientists has achieved a major breakthrough in Alzheimer’s disease research. The study found that by blocking or boosting a single key protein, the brain can be helped to fight the neurodegenerative damage caused by Alzheimer’s disease.

In experiments, researchers used an experimental drug that successfully helped mice with advanced Alzheimer’s disease restore their memory and learning abilities. The drug achieves this effect by restoring a key energy molecule in the brain.

IFLScience reported: “Scientists can’t believe it: an experimental drug helped mice with advanced Alzheimer’s disease regain their memory and ability to learn by restoring a key energy molecule in the brain.”

Mechanism of Action

The core finding of this research involves the role of a key protein in the brain. In Alzheimer’s patients, this protein’s function becomes impaired, leading to disruptions in nerve cell energy metabolism and cognitive decline.

Through pharmacological intervention, researchers successfully blocked the molecular pathway causing the protein’s dysfunction while simultaneously boosting protein levels that support the brain’s “cleanup crew.” This dual-action mechanism allows damaged nerve cells to recover their function.

Scientific Significance

This discovery has attracted widespread attention in the scientific community for several key reasons:

1. Single target: Unlike existing Alzheimer’s drugs that require multi-target intervention, this research only needs to target a single protein to produce significant effects
2. Late-stage reversal: Experiments show that memory function can potentially be restored even in advanced stages of the disease
3. Novel pathway: The research reveals a new connection between brain energy metabolism and Alzheimer’s disease, providing an entirely new direction for drug development

Clinical Prospects

Although these findings are still at the animal testing stage, the research team says that development of related drugs is being accelerated. Alzheimer’s disease affects more than 55 million people worldwide, and there is currently no effective cure.

Scientists caution that it typically takes several years to move from animal experiments to human clinical trials, and success in animal models does not guarantee the same results in humans. However, this discovery undoubtedly injects new hope into the field of Alzheimer’s research.

Sources: ScienceDaily · IFLScience

A landmark brain imaging study has identified three distinct neurobiological subtypes of Attention-Deficit/Hyperactivity Disorder (ADHD), one of which manifests as a significantly more extreme pattern of brain activity. This discovery could fundamentally transform how ADHD is diagnosed and treated, paving the way for precision medicine in this field.

Research Background

ADHD is one of the most common neurodevelopmental disorders worldwide, affecting millions of children and adults. Despite extensive research and widespread recognition, ADHD exhibits significant clinical heterogeneity — patients display markedly different types and severities of symptoms. For decades, the medical community has largely treated ADHD as a single condition, employing a “one-size-fits-all” approach to diagnosis and treatment.

Three Distinct Subtypes

Using advanced functional brain imaging technology, the research team conducted systematic brain scan analyses on a large cohort of ADHD patients. The study identified three clearly distinguishable subtypes based on brain activity patterns:

1. Classic Inattentive Type: Characterized primarily by reduced activity in the prefrontal cortex, correlating with core symptoms of difficulty maintaining attention and easy distractibility.

2. Impulsive-Hyperactive Dominant Type: Shows abnormal activity patterns in the basal ganglia and motor cortex, closely associated with impulsive behaviors and hyperactivity symptoms.

3. Extreme Combined Type: The most severe subtype identified in the study, patients exhibit widespread abnormalities in brain network connectivity, involving dysfunction across multiple brain regions’ coordinated activity. This subtype presents more severe clinical symptoms and shows relatively poorer response to conventional treatments.

Clinical Implications

This finding carries significant clinical value. First, it challenges the traditional conception of ADHD as a unitary disorder, suggesting that clinicians should develop personalized treatment plans based on each patient’s neurobiological subtype.

For patients with the extreme combined subtype, the study suggests that more intensive, comprehensive intervention strategies may be necessary, potentially combining medication, behavioral therapy, and neurofeedback training. For the other two subtypes, treatment selection can be more targeted toward the approaches most likely to be effective.

Research Outlook

The research team noted that this discovery is just the beginning. They plan to further expand their study sample to validate the prevalence of these subtypes across different populations and explore how each subtype responds to specific treatment protocols.

Neuroscience experts describe this study as representing a pivotal turning point in ADHD research. By identifying distinct neurobiological subtypes, the medical community may finally transition from empirical treatment approaches toward precision medicine, ultimately providing each ADHD patient with the most appropriate treatment strategy.

Source: The Washington Post

A research team at Cold Spring Harbor Laboratory has achieved a significant breakthrough in Alzheimer’s disease treatment. They found that blocking a protein called PTP1B can improve learning and memory in a mouse model of Alzheimer’s disease, while helping the brain’s immune cells clear harmful amyloid-β (Aβ) plaques.

From Discovery to Breakthrough

The study’s lead investigator, Professor Nicholas Tonks at Cold Spring Harbor Laboratory, first discovered PTP1B in 1988 and has spent decades studying its role in health and disease. In this latest work, Tonks collaborated with graduate student Yuxin Cen and postdoctoral fellow Steven Ribeiro Alves to find that PTP1B interacts with another protein called spleen tyrosine kinase (SYK).

SYK helps control microglia — the brain’s immune cells — which are responsible for clearing Aβ plaques. “Over the course of the disease, these cells become exhausted and less effective,” says Cen. “Our results suggest that PTP1B inhibition can improve microglial function, clearing up Aβ plaques.”

Multi-Faceted Treatment Potential

Alzheimer’s disease is strongly associated with obesity and type 2 diabetes, both of which are recognized risk factors for the condition. Since PTP1B is already considered a therapeutic target for metabolic disorders, this discovery could offer a broader treatment strategy for Alzheimer’s.

Current therapies for Alzheimer’s largely focus on reducing Aβ buildup, but their benefits are often limited for many patients. “Using PTP1B inhibitors that target multiple aspects of the pathology, including Aβ clearance, might provide an additional impact,” says Ribeiro Alves.

Moving Toward the Clinic

The Tonks lab is now collaborating with DepYmed, Inc. to develop PTP1B inhibitors for several medical applications. For Alzheimer’s disease, Tonks envisions combining these inhibitors with existing approved drugs. “The goal is to slow Alzheimer’s progression and improve quality of life of the patients,” he said.

This research opens an important avenue for developing new Alzheimer’s treatments. Given the existing research foundation for PTP1B inhibitors in metabolic diseases, the clinical translation pathway may be smoother than for entirely new therapeutic targets.

Source: ScienceDaily

April 28, 2026 — A groundbreaking study has successfully created the first “smell map” of olfactory receptors in the human nasal cavity, revealing the intricate mechanisms by which the human olfactory system perceives and distinguishes tens of thousands of different odors. Published in a leading academic journal, this research opens new directions for neurobiology and olfactory science.

Research Background

The human olfactory system is one of the most complex and mysterious sensory systems. The human nasal cavity contains approximately 400 different types of olfactory receptors, each of which can respond to specific odor molecules. However, for a long time, scientists have not understood how these receptors are arranged in the nasal cavity and how they work together to identify and distinguish such a vast spectrum of odors.

Previous research focused primarily on animal models, particularly mice and fruit flies. These studies indicated that the spatial arrangement of olfactory receptors in the nasal cavity correlates with their response characteristics to different odors, but the distribution pattern of human olfactory receptors had never been precisely mapped.

Breakthrough Findings

The research team used advanced molecular imaging techniques and genomic sequencing methods to create the first complete spatial distribution map of olfactory receptors in the human nasal cavity. The study found that different olfactory receptors are not randomly distributed — rather, they form an organized “map” structure in the nasal cavity based on the odor characteristics they respond to.

Specifically, receptors that respond to similar odor features tend to cluster together spatially, forming distinct “odor perception zones.” This spatial organization pattern is analogous to retinal arrangement in the visual system, suggesting that the human olfactory system has evolved a highly organized information processing mechanism.

Scientific Significance

This discovery has profound scientific implications. First, it provides an entirely new perspective on understanding the molecular basis of human olfaction, explaining why humans can identify specific odors from trillions of possible chemical molecules. Second, the discovery of this “smell map” may provide new targets for diagnosing and treating olfactory disorders.

Additionally, this research could drive the development of artificial olfaction technology and odor-sensing devices. By mimicking the spatial organization pattern of human olfactory receptors, researchers can design more efficient and sensitive electronic olfactory systems for applications in food safety testing, environmental monitoring, and medical diagnostics.

The research team stated that the next step is to investigate in depth how these olfactory receptors convert chemical signals into neural signals, and how the brain interprets these signals to produce olfactory perception.

Source: Medical Xpress, EurekAlert!

On April 28, 2026, a research team at the Massachusetts Institute of Technology (MIT) announced a breakthrough in optical technology — scientists have successfully transformed chaotic laser light into a high-precision brain imaging tool. The self-organizing “pencil beam” laser technology opens entirely new pathways for targeted neurological disease treatment.

The core breakthrough of this technology lies in exploiting the self-organizing effects that occur when laser light propagates through specific media. Researchers discovered that when chaotic laser light passes through carefully designed scattering media, it can spontaneously form a highly focused narrow beam precise enough to penetrate the skull and accurately image deep brain structures. This discovery overturns the traditional assumption that chaotic laser light cannot be used for precision imaging.

According to ScienceDaily, this imaging tool can deliver higher spatial resolution than existing functional MRI (fMRI) while offering the advantage of real-time dynamic monitoring. This means doctors can observe brain activity under more physiologically realistic conditions, providing more precise target localization for diagnosing and treating neurodegenerative diseases such as Parkinson’s, Alzheimer’s, and epilepsy.

GEN Bio noted that this pencil beam laser technology could help researchers design more precise brain-targeted therapies. One of the greatest challenges in traditional brain treatment is how to precisely intervene in diseased areas without damaging healthy brain tissue — the high-precision imaging capability of this new technology provides a key tool for solving this problem.

The MIT research team stated that the technology has completed proof-of-concept testing in laboratory settings, with animal experiments planned next to evaluate its imaging performance in live brain tissue. If clinical trials proceed smoothly, the technology could be translated into clinical diagnostic equipment within the coming years.

This research achievement not only represents a major breakthrough in the field of optical imaging but also provides a novel technical platform for cross-disciplinary research in brain science and neurological medicine, heralding the arrival of a new era of non-invasive precision brain intervention.

Source: ScienceDaily, Photonics Spectra, GEN Bio

A research team at Ohio State University has published a groundbreaking study suggesting that human infants may already possess two complex cognitive functions at birth. This finding challenges the long-held view in developmental psychology that these abilities must be gradually acquired through postnatal experience, offering a new perspective on the innate architecture of the human brain.

Research Background and Methods

The research team conducted systematic observations of newborn brain activity using advanced neuroimaging technology and behavioral experiments. The study employed functional near-infrared spectroscopy (fNIRS) and other non-invasive brain imaging techniques to record neural responses to specific stimuli without disrupting the infants’ natural state.

Researchers designed two experimental paradigms to test infants’ cognitive processing capabilities when exposed to social stimuli (such as faces and voices) versus non-social physical stimuli (such as object motion trajectories). Through data analysis of a large newborn sample, the team arrived at surprising results.

Key Findings

The study revealed that newborns demonstrate two cognitive functions at birth that were previously thought to require postnatal development:

The first is selective social attention — infants can prioritize and process information related to human social interaction, such as facial expressions and vocal tones. This ability enables newborns to quickly identify signals relevant to human communication from a complex array of environmental stimuli.

The second is nascent causal reasoning — infants can form basic expectations and judgments about causal relationships between objects. When observing a scene where one object strikes another, newborns’ brains activate specific neural circuits, indicating they already possess a preliminary understanding of causal relationships in the physical world.

Scientific Significance

The significance of this study lies in its contribution to the classic “nature vs. nurture” debate. The research suggests that the human brain is not a blank slate (tabula rasa) but rather comes equipped at birth with specific cognitive architectures that enable infants to rapidly adapt to and learn from key information in their social and physical environments.

The lead researcher noted that these innate cognitive functions lay the foundation for subsequent complex learning. They act like “pre-installed programs” in the brain, allowing infants to begin meaningful interaction with their surroundings within a very short time after birth.

Implications for Child Development

This discovery has profound implications for early childhood education and intervention strategies. If certain cognitive abilities are indeed innate, the window for early intervention may be earlier than previously thought. For early screening and diagnosis of neurodevelopmental conditions such as autism spectrum disorder, this research offers a new approach — detecting abnormalities in these innate cognitive functions could identify developmental risks shortly after birth.

Future Research Directions

The research team said future work will focus on understanding variations in these innate cognitive functions across different populations and their relationship to later cognitive development. Researchers also plan to explore the neurogenetic basis of these functions to further understand the evolutionary history of human cognitive abilities.

Source: Medical Xpress, Ohio State News